Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient populationEncouraging safety and ...

Good morning. Welcome to today's conference call to discuss Kimberly-Clark's acquisition of Kenvue. [Operator Instructions]. With that, I would now like to turn the call over to Chris Jakubik, ...

Q3 2025 Earnings Call November 3, 2025 8:30 AM ESTCompany ParticipantsJohn Kasel - President, CEO & DirectorWilliam Thalman ...

First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...

A medspa playbook to turn attention into bookings—clear pages, local SEO, and one-screen scheduling. Start booking more clients today!

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, ...

Title: A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study ...

On November 3, 2025, Terns Pharmaceuticals announced that data from the Phase 1 CARDINAL trial of TERN-701 in patients with relapsed/refractory chronic myeloid leukemia has been selected for oral ...

ORLANDO, FLORIDA / ACCESS Newswire / October 30, 2025 / RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, Connect or the Company ...

Q3 2025 Earnings Call Transcript October 30, 2025 Capital Clean Energy Carriers Corp. beats earnings expectations. Reported EPS is $0.39, expectations were $0.38. Operator: Thank you for standing by, ...

Hyperke Growth Partners has released detailed case study results demonstrating how direct-to-consumer brands can secure hundreds of retail placement opportunities through systematic outreach to ...